Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma

Eric P. Grewal, Courtney L. Erskine, Wendy K. Nevala, Jacob B. Allred, Carrie A. Strand, Lisa A. Kottschade, Robert R. McWilliams, Roxana S. Dronca, Adam J. Yakovich, Svetomir N. Markovic, Matthew S. Block

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: We tested the safety and immunogenicity of a novel vaccine in patients with resected high-risk melanoma. Patients & methods: HLA-A2-positive patients with resected Stage II-IV melanoma were randomized to receive up to three vaccinations of melanoma-associated peptide (MART-1a) combined with a stable oil-in-water emulsion (SE) either with the Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA-SE-Schedule 1) or alone (SE-Schedule 2). Safety and immunogenicity of the vaccines were monitored. Results: A total of 23 patients were registered. No treatment-related grade 3 or higher adverse events were observed. Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively. Conclusion: Both vaccine schedules were well-tolerated and resulted in an increase in MART-1a-specific T cells. Clinical Trial registration: NCT02320305 (ClinicalTrials.gov).

Original languageEnglish (US)
Pages (from-to)983-995
Number of pages13
JournalImmunotherapy
Volume12
Issue number13
DOIs
StatePublished - Sep 2020

Keywords

  • MART-1
  • Phase I
  • T cell
  • glucopyranosyl lipid A
  • immunotherapy
  • melanoma
  • peptide
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma'. Together they form a unique fingerprint.

Cite this